M2AS34 Stock Overview
Develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Masimo Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.47 |
| 52 Week High | US$35.40 |
| 52 Week Low | US$18.00 |
| Beta | 1.01 |
| 1 Month Change | 64.14% |
| 3 Month Change | 61.38% |
| 1 Year Change | 81.42% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| M2AS34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -1.4% | -1.6% | -3.1% |
| 1Y | 81.4% | 7.2% | -11.4% |
Return vs Industry: M2AS34 exceeded the BR Medical Equipment industry which returned 6.6% over the past year.
Return vs Market: M2AS34 exceeded the BR Market which returned -11.4% over the past year.
Price Volatility
| M2AS34 volatility | |
|---|---|
| M2AS34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in BR Market | 9.5% |
| 10% least volatile stocks in BR Market | 2.8% |
Stable Share Price: M2AS34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine M2AS34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 3,800 | Michelle Brennan | www.masimo.com |
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions.
Masimo Corporation Fundamentals Summary
| M2AS34 fundamental statistics | |
|---|---|
| Market cap | R$55.38b |
| Earnings (TTM) | R$478.27m |
| Revenue (TTM) | R$12.43b |
115.5x
P/E Ratio4.4x
P/S RatioIs M2AS34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M2AS34 income statement (TTM) | |
|---|---|
| Revenue | US$2.04b |
| Cost of Revenue | US$1.02b |
| Gross Profit | US$1.02b |
| Other Expenses | US$943.80m |
| Earnings | US$78.60m |
Last Reported Earnings
Sep 28, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.47 |
| Gross Margin | 50.05% |
| Net Profit Margin | 3.85% |
| Debt/Equity Ratio | 52.8% |
How did M2AS34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 17:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/28 |
| Annual Earnings | 2023/12/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Masimo Corporation is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Polark | Baird |
| Ishan Majumdar | Baptista Research |
| Charley Jones | Barrington Research Associates, Inc. |